Table 1:

Characteristics of patients with long-term opioid use in British Columbia, historical control cohort versus policy cohort*

CharacteristicNo. (%) of patientsASD, %
Historical control cohort
n = 68 429
Policy cohort
n = 68 113
Demographic
Sex
 Female36 894 (53.9)36 903 (54.2)0.5
 Male31 535 (46.1)31 210 (45.8)0.5
Age, yr
 < 25473 (0.7)388 (0.6)1.5
 25–396376 (9.3)5925 (8.7)2.2
 40–5420 946 (30.6)19 848 (29.1)3.2
 55–6418 779 (27.4)19 249 (28.3)1.8
 65–7411 670 (17.0)12 391 (18.2)3.0
 75–846921 (10.1)7015 (10.3)0.6
 ≥ 853264 (4.8)3297 (4.8)0.3
Low income13 222 (19.3)12 683 (18.6)1.8
Place of residence
 Rural10 766 (15.7)10 726 (15.7)0.04
 Urban57 663 (84.3)57 387 (84.2)0.04
Medical history in 365 d before follow-up
Psychiatric illness14 994 (21.9)14 152 (20.8)2.8
Chronic pain condition
 Mechanical neck or back pain9738 (14.2)9815 (14.4)0.5
 Mechanical low back pain12 900 (18.8)13 477 (19.8)2.4
 Osteoarthritis6778 (9.9)6723 (9.9)0.1
 Rheumatoid arthritis1619 (2.4)1566 (2.3)0.4
 Diabetic neuropathy239 (0.3)262 (0.4)0.6
 Peripheral neuropathy230 (0.3)262 (0.4)0.8
 Lumbar radiculopathy182 (0.3)221 (0.3)1.1
 Alcohol dependence or abuse1307 (1.9)1311 (1.9)0.1
 Opioid use disorder821 (1.2)931 (1.4)1.5
Romano comorbidity score0.8
 036 447 (53.3)36 000 (52.8)
 117 146 (25.1)16 965 (24.9)0.3
 27074 (10.3)7320 (10.7)1.3
 ≥ 37762 (11.3)7828 (11.5)0.5
Prescription history in 180 d before follow-up
Opioid substitution therapy943 (1.4)909 (1.3)0.4
Maximum daily opioid analgesic dosage dispensed, MME
 Lower (≤ 50)41 679 (60.9)42 565 (62.5)3.3
 Intermediate (> 50 to 90)12 987 (19.0)12 753 (18.7)0.7
 High (> 90 to 200)8598 (12.6)8144 (12.0)1.9
 Very high (> 200)5165 (7.5)4651 (6.8)2.8
Intensity of opioid analgesic use
 Lower (< 90 days’ supply)10 648 (15.6)10 471 (15.4)0.5
 Higher (≥ 90 days’ supply)57 781 (84.4)57 642 (84.6)0.5
Sedative/hypnotic medication use30 291 (44.3)28 737 (42.2)4.2
  • Note: ASD = absolute standardized difference, MME = milligrams of morphine equivalents.

  • * Patient characteristics were evaluated before follow-up.

  • Excluding low back pain.

  • Based on days’ supply dispensed.